择期手术患者术前长时间禁食:为何我们应减少禁食时间?
Prolonged preoperative fasting in elective surgical patients: why should we reduce it?
作者信息
Pimenta Gunther Peres, de Aguilar-Nascimento José Eduardo
机构信息
José Eduardo de Aguilar-Nascimento, Department of Surgery, Federal University of Mato Grosso, Rodovia Helder Cândia 2755, Condomínio Country,15, 78048-150; Cuiabá-MT, Brazil. Email:
出版信息
Nutr Clin Pract. 2014 Feb;29(1):22-8. doi: 10.1177/0884533613514277. Epub 2013 Dec 11.
Despite the abundance of evidence to the contrary, 6-8 hours of total preoperative fasting is still considered essential by many surgeons and anesthesiologists, based on the strength of old concepts. Patients frequently end up fasting for 12 hours or more because of delays and changes in operating room schedules. The metabolic response to long fasting leads to intensification of the organic response occurring after trauma, which is mainly manifested as increased insulin resistance, an acute-phase response, and loss of lean body mass. In fact, there has not been any evidence indicating that a shorter fast of 2-3 hours, which includes oral clear or carbohydrate (CHO)-rich (12.5% carbohydrates, 50 kcal/100 mL) fluids, results in an increased risk of aspiration, regurgitation, or related morbidity compared with the standard policy of "nil by mouth after midnight." In addition, preoperative treatment with CHO-rich fluids may reduce postoperative discomfort and, for patients undergoing major abdominal surgery, may decrease the duration of postoperative hospitalization. New formulas for preoperative oral fluids containing amino acid or protein such as glutamine or whey protein are also potential candidates for early preoperative treatment and merit further study.
尽管有大量相反的证据,但基于旧观念的影响,许多外科医生和麻醉医生仍认为术前禁食6 - 8小时是必不可少的。由于手术室日程安排的延误和变动,患者常常最终禁食12小时或更长时间。长时间禁食的代谢反应会导致创伤后机体反应加剧,主要表现为胰岛素抵抗增加、急性期反应以及瘦体重丢失。事实上,没有任何证据表明,与“午夜后禁食禁水”的标准政策相比,短至2 - 3小时的禁食(包括饮用清亮液体或富含碳水化合物(CHO)的液体(12.5%碳水化合物,50千卡/100毫升))会增加误吸、反流或相关发病率的风险。此外,术前饮用富含碳水化合物的液体可能会减轻术后不适,对于接受腹部大手术的患者,还可能缩短术后住院时间。含有氨基酸或蛋白质(如谷氨酰胺或乳清蛋白)的术前口服液体新配方也是术前早期治疗的潜在选择,值得进一步研究。